Here’s Respiree! They’re a Singapore-founded healthtech company developing AI platforms to manage disease progression across the patient’s healthcarecare journey. Now, they just raised a $11.6M Series A!

• Their solutions are available in the US, Australia, and across APAC. 

Investor check. We Venture Capital and ClavystBio led the round. 

• The round also saw participation from Adaptive Capital Partners and conversion of note securities from Mayo Clinic’s Mayo Foundation for Medical Research.
• Greenwillow Capital Management, Seeds Capital, and she1K angel investment also joined in. 

‍

🫀 Take care 

One of Respiree’s flagship AI platforms can help healthcare professionals detect patient deterioration earlier, including rapid response calls in general wards and unplanned ICU transfers.

They’re seeking clearance from the US Food and Drug Administration for their model right now. 

• Their goal is to integrate the model into their proprietary platform 1Bio. 
•  The 1Bio platform uses data from electronic health records and their proprietary US-patented and FDA-cleared sensors to longitudinal insights into disease progression.

‍

❤️‍🔥 More on Respiree

Respiree is an AI/ML health tech company with a mix of hardware and software solutions that are designed to help clinicians improve patient outcomes.

• They have connected wearables that can capture a broad range of cardio-respiratory measures. 
• Oh, and they also have a centralized electronic health record platform that can consolidate real-time analytics and data from multiple sources. 

‍

🩺 What’s next?

Respiree plans to expand their solutions to new markets like the Gulf Cooperation Council and Thailand. 

• They’ll also use some of the $$$ to strengthen operations with existing channel partners and accelerate the development of new business relationships.